Discussion of any compound's effects refers to outcomes observed in clinical or preclinical studies, not anecdotal reports.
GLP-1 receptor agonists reduce body weight, but not all weight loss is equal. Visceral adipose tissue (VAT) drives cardiometabolic risk. Two peptides, tesamorelin and AOD-9604, are often discussed for VAT reduction. This article examines their evidence bases.
Why this comparison matters
Semaglutide and tirzepatide produce substantial total weight loss. Yet residual VAT remains a concern. A 2021 New England Journal of Medicine analysis by Wilding and colleagues showed that semaglutide reduced VAT, but the proportion of VAT to subcutaneous fat changed little. Patients and clinicians seek adjuncts that preferentially target visceral fat.
Tesamorelin, a growth hormone-releasing hormone analog, is FDA-approved for excess abdominal fat in HIV-associated lipodystrophy. AOD-9604, a fragment of human growth hormone, is not approved for any indication. Both are used off-label alongside GLP-1s. The critical question is whether either has trial data supporting a visceral-fat-specific effect.
Study designs and subjects
Tesamorelin's pivotal trials enrolled HIV patients with lipodystrophy. The 2011 phase III trial by Falutz and colleagues, published in AIDS, randomized 404 subjects to tesamorelin 2 mg daily or placebo for 26 weeks. The primary endpoint was VAT change by CT scan. A 2016 Journal of Clinical Endocrinology & Metabolism paper by Stanley and colleagues extended this to 52 weeks.
AOD-9604 has no phase III trials for visceral fat. The most cited human study is a 2013 Obesity paper by Heymsfield and colleagues. It was a 24-week randomized trial in 536 obese subjects. The primary endpoint was weight loss, not VAT. A 2007 Journal of Clinical Endocrinology & Metabolism study by Stier and colleagues examined AOD-9604 in 300 subjects for 12 weeks, again focused on weight.
No head-to-head trial compares tesamorelin and AOD-9604. No trial combines either with a GLP-1 agonist. Evidence quality for tesamorelin's VAT effect is a 2 of 3. For AOD-9604's VAT effect, it is a 1 of 3.
Reported findings
In the 2011 Falutz trial, tesamorelin reduced VAT by 15.4% versus a 5.3% increase with placebo (p<0.001). Subcutaneous fat did not change significantly. IGF-1 levels rose, confirming target engagement. The 2016 extension showed VAT reduction persisted at 52 weeks. Adverse events included arthralgia, injection-site reactions, and hyperglycemia.
AOD-9604's 2013 Heymsfield trial showed weight loss of 2.7 kg versus 1.5 kg with placebo (p=0.04). No CT-measured VAT data were reported. The 2007 Stier trial found no significant weight loss difference at the highest dose. A 2020 Peptides review by Chang and colleagues noted that AOD-9604's lipolytic effects are primarily from rodent models.
Tesamorelin's VAT data are direct and replicated. AOD-9604's VAT data are absent in humans. This distinction is often overlooked in online discussions.
Authors' conclusions
Falutz and colleagues concluded tesamorelin significantly and selectively reduces VAT in HIV lipodystrophy. Stanley and colleagues emphasized durability and a manageable safety profile. They did not claim generalizability to non-HIV populations, but subsequent off-label use has expanded.
Heymsfield and colleagues concluded AOD-9604 produced modest weight loss but did not claim VAT reduction. Stier and colleagues were more cautious, noting no dose-response for weight. No author group has recommended AOD-9604 for visceral fat specifically.
In a 2022 review in Endocrine Reviews, Makimura and colleagues positioned tesamorelin as the only peptide with robust VAT data, while noting that GLP-1 combinations are unstudied. This is the current evidence ceiling.
Annotated critique
Tesamorelin's trials used CT imaging, the gold standard for VAT. The effect size was clinically meaningful. However, the population was HIV-positive with baseline VAT excess. Whether the same magnitude occurs in GLP-1-treated obesity is unknown. The 2 mg dose was not titrated, and hyperglycemia risk warrants caution with GLP-1s.
AOD-9604 trials used DEXA or weight scales, not CT. Any VAT effect is inferred from preclinical data. The 2013 trial's weight loss was statistically but not clinically significant. The evidence for AOD-9604 as a visceral fat agent is a 1 of 3. Its safety profile appears benign, but absence of harm is not proof of safety.
Neither peptide has been studied with semaglutide or tirzepatide. The Medicare coverage shift for weight-loss drugs may increase interest in such combinations, but data are absent. The potential bone benefits of tesamorelin during menopause add another layer, but this is not a VAT outcome.
Implications and limits
Tesamorelin has direct VAT evidence; AOD-9604 does not. This does not make tesamorelin safe or effective for all. Its hyperglycemia risk may compound GLP-1 effects. No trial has tested this. The comparison with tirzepatide highlights that GLP-1s alone reduce VAT, but the residual risk is undefined.
Other peptides like CJC-1295 and MOTS-c lack human VAT data. Stacking unstudied compounds is speculative. The 2022 Makimura review rated tesamorelin's evidence as moderate, AOD-9604's as low. This is the key takeaway for clinicians.
Information here reflects published findings at the time of writing and may be superseded by newer research.
Common questions
Does tesamorelin reduce visceral fat in non-HIV patients?
No randomized trial has tested tesamorelin in non-HIV populations. The 2011 Falutz trial and 2016 Stanley extension enrolled only HIV patients with lipodystrophy. Off-label use assumes a class effect, but growth hormone axis differences may alter response. A 2022 Endocrine Reviews paper by Makimura and colleagues called for trials in obesity without HIV. Until then, the evidence is indirect.
Is AOD-9604 effective for visceral fat loss?
Human trials of AOD-9604 did not measure visceral fat by CT. The 2013 Heymsfield trial in Obesity reported modest weight loss but no VAT data. Preclinical rodent studies show lipolysis, but translation to human VAT is unproven. A 2020 Peptides review by Chang and colleagues rated the human evidence as low quality. AOD-9604 cannot be recommended for visceral fat reduction based on current data.
Can I stack tesamorelin with semaglutide?
No clinical trial has combined tesamorelin with any GLP-1 agonist. Both drugs can raise glucose and heart rate. Additive effects are unknown. The 2011 Falutz trial excluded patients on diabetes medications. A 2016 Journal of Clinical Endocrinology & Metabolism paper noted hyperglycemia as a tesamorelin adverse event. Combination use is experimental and should occur only in research settings.
What are the side effects of tesamorelin?
The 2011 Falutz trial reported arthralgia (13%), injection-site reactions (8%), and hyperglycemia (4%). IGF-1 elevation may cause fluid retention and carpal tunnel syndrome. The 2016 Stanley extension found no new safety signals at 52 weeks. Long-term cancer risk is theoretical due to growth hormone pathway activation. No malignancy signal emerged in trials, but follow-up was limited. Side-effect data for many peptides is sparse.
Discussion of any compound's effects refers to outcomes observed in clinical or preclinical studies, not anecdotal reports.